| Bioactivity | CP-31398 can stabilize the active conformation of p53 and promote p53 activity in cancer cells with either mutant or wild-type p53. In addition, CP-31398 can upregulate p53 target genes, such as p21WAF1/Cip1 and KILLER/DR5. CP-31398 exerts an inhibitory effect on tumor growth[1][2][3]. |
| Invitro | CP-31398 (36.75 μM，16 小时) 可在 p53 突变细胞中诱导 p21 的表达[1]。CP-31398 (15 μg/mL，20 小时) 可在 SW480 细胞中诱导凋亡和细胞周期停滞[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> CP-31398 相关抗体: Western Blot Analysis[1] Cell Line: |
| In Vivo | CP-31398 (100 mg/kg，口服，每天两次，共 7 天) 在异种移植小鼠模型中表现出显著的抗肿瘤活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 259199-65-0 |
| Formula | C22H26N4O |
| Molar Mass | 362.47 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. B A Foster, et al. Pharmacological rescue of mutant p53 conformation and function. Science. 1999 Dec 24;286(5449):2507-10. [2]. Rishu Takimoto, et al. The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis of Human Cancer Cells and Can Stabilize Wild-Type p53 Protein. Cancer Biol Ther. Jan-Feb 2002;1(1):47-55. [3]. J Wischhusen, et al. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene. 2003 Nov 13;22(51):8233-45. |